Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma

Phase 2

Completed

Conditions: Retinoblastoma

First Posted Date: 2003-07-18

Last Posted Date: 2011-10-04

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 4

Registration Number: NCT00004006

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Phase 3

Completed

Conditions: Recurrent Uterine Corpus Carcinoma
Stage IIIA Uterine Corpus Cancer AJCC v7
Stage IIIB Uterine Corpus Cancer AJCC v7
Stage IIIC Uterine Corpus Cancer AJCC v7
Stage IVB Uterine Corpus Cancer AJCC v7
Stage IVA Uterine Corpus Cancer AJCC v7

Interventions: Drug: Cisplatin
Drug: Carboplatin
Drug: Doxorubicin Hydrochloride
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Biological: Pegfilgrastim
Other: Quality-of-Life Assessment

First Posted Date: 2003-07-09

Last Posted Date: 2021-10-19

Lead Sponsor: GOG Foundation

Target Recruit Count: 1381

Registration Number: NCT00063999

Locations: 🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸
Mason District Hospital, Havana, Illinois, United States
🇺🇸
Greater Baltimore Medical Center, Baltimore, Maryland, United States

and more 640 locations

Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Phase 2

Completed

Conditions: Primary Peritoneal Cavity Cancer
Fallopian Tube Cancer
Ovarian Cancer

First Posted Date: 2003-07-01

Last Posted Date: 2015-12-23

Lead Sponsor: AGO Study Group

Target Recruit Count: 105

Registration Number: NCT00031954

Locations: 🇩🇪
Zentralkrankenhaus, Bremen, Germany
🇩🇪
Medizinische Klinik I, Dresden, Germany
🇩🇪
Evangelisches Krankenhaus, Dusseldorf, Germany

and more 15 locations

Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

First Posted Date: 2003-07-01

Last Posted Date: 2021-09-09

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 1

Registration Number: NCT00028938

Locations: 🇺🇸
Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States

Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: topotecan hydrochloride
Radiation: WBRT

First Posted Date: 2003-06-30

Last Posted Date: 2016-12-07

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 27

Registration Number: NCT00028925

Locations: 🇺🇸
Siouxland Hematology-Oncology, Sioux City, Iowa, United States
🇺🇸
CCOP - Duluth, Duluth, Minnesota, United States
🇺🇸
CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States

and more 21 locations

Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cavity Cancer

First Posted Date: 2003-06-27

Last Posted Date: 2020-04-08

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 50

Registration Number: NCT00030446

Locations: 🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada
🇨🇦
Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
British Columbia Cancer Agency - Centre for the Southern Interior, Kelowna, British Columbia, Canada

and more 5 locations

Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Peritoneal Neoplasms
Fallopian Tube Neoplasms

Interventions: Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2003-06-27

Last Posted Date: 2010-04-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 39

Registration Number: NCT00063401

Locations: 🇺🇸
ImClone Investigational Site, Philadelphia, Pennsylvania, United States

Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: Tarceva (OSI-774)
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2003-06-25

Last Posted Date: 2016-05-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00063258

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: gefitinib
Drug: paclitaxel

First Posted Date: 2003-06-06

Last Posted Date: 2016-12-14

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 65

Registration Number: NCT00062062

Locations: 🇺🇸
Promedica Cancer Center at Flower Hospital, Sylvania, Ohio, United States
🇺🇸
Medical College of Ohio Cancer Institute, Toledo, Ohio, United States
🇺🇸
St. Vincent Mercy Medical Center, Toledo, Ohio, United States

and more 135 locations

Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: celecoxib
Other: Placebo
Drug: paclitaxel

First Posted Date: 2003-06-06

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 7

Registration Number: NCT00062179

Locations: 🇺🇸
New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy